Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Total Payout Ratio : 0.00 (As of Apr. 29, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Regenerx Biopharmaceuticals's current Total Payout Ratio is 0.00.

Regenerx Biopharmaceuticals Total Payout Ratio Historical Data

The historical data trend for Regenerx Biopharmaceuticals's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerx Biopharmaceuticals Total Payout Ratio Chart

Regenerx Biopharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Payout Ratio

Get a 7-Day Free Trial

1.10

Regenerx Biopharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regenerx Biopharmaceuticals's Total Payout Ratio

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerx Biopharmaceuticals's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Total Payout Ratio falls into.

Regenerx Biopharmaceuticals Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Regenerx Biopharmaceuticals's Total Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-1.727
	=	0.00

Regenerx Biopharmaceuticals's Total Payout Ratio for the quarter that ended in Mar. 2023 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-0.385
	=	0.00

Regenerx Biopharmaceuticals Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850

Website

https://www.regenerx.com

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Executives

Aptafin S P A	other: Member of 10% owner group	VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda	director	C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf	10 percent owner	26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove	director	C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein	director
Joseph C Mcnay	director	3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein	director
Dane R Saglio	officer: Chief Financial Officer
Aria Digital	10 percent owner	22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863